CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients’ plasma as potential noninvasive biomarkers of disease activity

References

• Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res. 2007;67(18):8865–9. doi:10.1158/0008-5472.can-07-0767.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006;12(13):3890–3895. doi:10.1158/1078-0432.CCR-05-2750.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Head and neck carcinoma immunotherapy: facts and hopes. Clin Cancer Res. 2017. doi:10.1158/1078-0432.ccr-17-1261.
   Web of Science ®Google Scholar
• Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845–852. doi:10.1200/jco.2012.43.6097.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. doi:10.1056/NEJMoa1602252.
   PubMed Web of Science ®Google Scholar
• Clarke MF. Clinical and therapeutic implications of cancer stem cells. N Engl J Med. 2019;380(23):2237–2245. doi:10.1056/NEJMra1804280.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer. 2003;39(10):1348–1354. doi:10.1016/s0959-8049(03)00235-1.
   PubMed Web of Science ®Google Scholar
• Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients. Clin Cancer Res. 2018;24(4):896–905. doi:10.1158/1078-0432.CCR-17-2664.
   PubMed Web of Science ®Google Scholar
• Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156–172. doi:10.1038/cr.2009.5.
   PubMed Web of Science ®Google Scholar
• Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999;59:5356–5364.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, Ferrone CR, Favoino E, Koya Y, Campoli MR, et al. CSPG4 in cancer: multiple roles. Curr Mol Med. 2010;10(4):419–429. doi:10.2174/156652410791316977.
   PubMed Web of Science ®Google Scholar
• Ilieva KM, Cheung A, Mele S, Chiaruttini G, Crescioli S, Griffin M, Nakamura M, Spicer JF, Tsoka S, Lacy KE, et al. Chondroitin sulfate proteoglycan 4 and its potential as an antibody immunotherapy target across different tumor types. Front Immunol. 2017;8:1911. doi:10.3389/fimmu.2017.01911.
   PubMed Web of Science ®Google Scholar
• Wang L, Zuo X, Xie K, Wei D. The role of CD44 and cancer stem cells. Methods Mol Biol. 2018;1692:31–42. doi:10.1007/978-1-4939-7401-6_3.
   PubMedGoogle Scholar
• Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007;104(3):973–978. doi:10.1073/pnas.0610117104.
   PubMed Web of Science ®Google Scholar
• Bourguignon LY, Lokeshwar VB, He J, Chen X, Bourguignon GJ. A CD44-like endothelial cell transmembrane glycoprotein (GP116) interacts with extracellular matrix and ankyrin. Mol Cell Biol. 1992;12(10):4464–4471. doi:10.1128/MCB.12.10.4464.
   PubMed Web of Science ®Google Scholar
• Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA. 1992;89(24):12160–12164. doi:10.1073/pnas.89.24.12160.
   PubMed Web of Science ®Google Scholar
• Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem. 2002;277(7):4589–4592. doi:10.1074/jbc.R100038200.
   PubMed Web of Science ®Google Scholar
• Iida N, Bourguignon LY. New CD44 splice variants associated with human breast cancers. J Cell Physiol. 1995;162(1):127–133. doi:10.1002/jcp.1041620115.
   PubMed Web of Science ®Google Scholar
• Wang JL, Su WY, Lin YW, Xiong H, Chen YX, Xu J, Fang JY. CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis. Oncotarget. 2017;8(8):12866–12876. doi:10.18632/oncotarget.14163.
   PubMedGoogle Scholar
• Qian C, Wang Y, Chen Y, Zeng L, Zhang Q, Shuai X, Huang K. Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles. Biomaterials. 2013;34(26):6175–6184. doi:10.1016/j.biomaterials.2013.04.056.
   PubMed Web of Science ®Google Scholar
• Sagawa K, Uwa N, Daimon T, Sakagami M, Tsujimura T. Expression of CD44 variant isoforms, CD44v3 and CD44v6, are associated with prognosis in nasopharyngeal carcinoma. J Laryngol Otol. 2016;130(9):843–849. doi:10.1017/s0022215116008525.
   PubMed Web of Science ®Google Scholar
• Spiegelberg D, Kuku G, Selvaraju R, Nestor M. Characterization of CD44 variant expression in head and neck squamous cell carcinomas. Tumour Biol. 2014;35(3):2053–2062. doi:10.1007/s13277-013-1272-3.
   PubMedGoogle Scholar
• Todoroki K, Ogasawara S, Akiba J, Nakayama M, Naito Y, Seki N, Kusukawa J, Yano H. CD44v3+/CD24- cells possess cancer stem cell-like properties in human oral squamous cell carcinoma. Int J Oncol. 2016;48(1):99–109. doi:10.3892/ijo.2015.3261.
   PubMed Web of Science ®Google Scholar
• Franzmann EJ, Weed DT, Civantos FJ, Goodwin WJ, Bourguignon LY. A novel CD44 v3 isoform is involved in head and neck squamous cell carcinoma progression. Otolaryngol Head Neck Surg. 2001;124(4):426–432. doi:10.1067/mhn.2001.114674.
   PubMed Web of Science ®Google Scholar
• Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, Christofori G, Heroult M, Augustin HG, Ponta H, et al. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood. 2009;114(25):5236–5244. doi:10.1182/blood-2009-04-219204.
   PubMed Web of Science ®Google Scholar
• Forster-Horvath C, Meszaros L, Raso E, Dome B, Ladanyi A, Morini M, Albini A, Timar J. Expression of CD44v3 protein in human endothelial cells in vitro and in tumoral microvessels in vivo. Microvasc Res. 2004;68(2):110–118. doi:10.1016/j.mvr.2004.05.001.
   PubMed Web of Science ®Google Scholar
• Faber A, Barth C, Hormann K, Kassner S, Schultz JD, Sommer U, Stern-Straeter J, Thorn C, Goessler UR. CD44 as a stem cell marker in head and neck squamous cell carcinoma. Oncol Rep. 2011;26(2):321–326. doi:10.3892/or.2011.1322.
   PubMed Web of Science ®Google Scholar
• Wang Z, von Au A, Schnolzer M, Hackert T, Zoller M. CD44v6-competent tumor exosomes promote motility, invasion and cancer-initiating cell marker expression in pancreatic and colorectal cancer cells. Oncotarget. 2016;7(34):55409–55436. doi:10.18632/oncotarget.10580.
   PubMedGoogle Scholar
• Van Hal NL, Van Dongen GA, Ten Brink CB, Heider KH, Rech-Weichselbraun I, Snow GB, Brakenhoff RH. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. Clin Cancer Res. 1999;5:3534–3541.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Wreesmann VB, Bourguignon LY. Association of CD44 V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer. Head Neck. 2007;29(6):550–558. doi:10.1002/hed.20544.
   PubMed Web of Science ®Google Scholar
• Franzmann EJ, Reategui EP, Pedroso F, Pernas FG, Karakullukcu BM, Carraway KL, Hamilton K, Singal R, Goodwin WJ. Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(7):1348–1355. doi:10.1158/1055-9965.EPI-06-0011.
   PubMed Web of Science ®Google Scholar
• Senbanjo LT, Chellaiah MA. CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol. 2017;5:18. doi:10.3389/fcell.2017.00018.
   PubMed Web of Science ®Google Scholar
• Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–383. doi:10.1083/jcb.201211138.
   PubMed Web of Science ®Google Scholar
• Abels ER, Breakefield XO. Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake. Cell Mol Neurobiol. 2016;36(3):301–312. doi:10.1007/s10571-016-0366-z.
   PubMed Web of Science ®Google Scholar
• Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30(6):836–848. doi:10.1016/j.ccell.2016.10.009.
   PubMed Web of Science ®Google Scholar
• Sharma P, Ludwig S, Muller L, Hong CS, Kirkwood JM, Ferrone S, Whiteside TL. Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma. J Extracell Vesicles. 2018;7(1):1435138. doi:10.1080/20013078.2018.1435138.
   PubMed Web of Science ®Google Scholar
• Theodoraki MN, Hoffmann TK, Whiteside TL. Separation of plasma-derived exosomes into CD3((+)) and CD3((-)) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients. Clin Exp Immunol. 2018;192(3):271–283. doi:10.1111/cei.13113.
   PubMed Web of Science ®Google Scholar
• Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood). 2013;238(3):324–338. doi:10.1177/1535370213480714.
   PubMed Web of Science ®Google Scholar
• Orian-Rousseau V, Sleeman J. CD44 is a multidomain signaling platform that integrates extracellular matrix cues with growth factor and cytokine signals. Adv Cancer Res. 2014;123:231–254. doi:10.1016/b978-0-12-800092-2.00009-5.
   PubMed Web of Science ®Google Scholar
• Ludwig S, Floros T, Theodoraki MN, Hong CS, Jackson EK, Lang S, Whiteside TL. Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer. Clin Cancer Res. 2017;23(16):4843–4854. doi:10.1158/1078-0432.CCR-16-2819.
   PubMed Web of Science ®Google Scholar
• Theodoraki MN, Hoffmann TK, Jackson EK, Whiteside TL. Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence. Clin Exp Immunol. 2018;194(1):67–78. doi:10.1111/cei.13157.
   PubMed Web of Science ®Google Scholar
• Theodoraki MN, Yerneni S, Gooding WE, Ohr J, Clump DA, Bauman JE, Ferris RL, Whiteside TL. Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. Oncoimmunology. 2019;8(7):1593805. doi:10.1080/2162402X.2019.1593805.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Exosomes and tumor-mediated immune suppression. J Clin Invest. 2016;126(4):1216–1223. doi:10.1172/JCI81136.
   PubMed Web of Science ®Google Scholar
• Hong CS, Funk S, Muller L, Boyiadzis M, Whiteside TL. Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer. J Extracell Vesicles. 2016;5(1):29289. doi:10.3402/jev.v5.29289.
   PubMed Web of Science ®Google Scholar
• Ludwig N, Razzo BM, Yerneni SS, Whiteside TL. Optimization of cell culture conditions for exosome isolation using mini-size exclusion chromatography (mini-SEC). Exp Cell Res. 2019;378(2):149–157. doi:10.1016/j.yexcr.2019.03.014.
   PubMed Web of Science ®Google Scholar
• Ludwig N, Hong C-S, Ludwig S, Azambuja JH, Sharma P, Theodoraki M-N, Whiteside TL. Isolation and analysis of tumor-derived exosomes. Cur Protoc Immunol. 2019;127(1):e91. doi:10.1002/cpim.91.
   PubMedGoogle Scholar
• Thery C, Witwer KW, Alcaraz E. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750. doi:10.1080/20013078.2018.1535750.
   PubMed Web of Science ®Google Scholar